HC
Han-Saem Cho
Principal Researcher at Gi Cell (지아이셀)
View Han-Saem's Contact Info for Free. Sign Up and Get 50 Free Contacts Per Month.Get Started for Free
Work Experience
Mar 2019 - Present · 5 years and 9 months
Principal Researcher
Jan 2020 - Present · 4 years and 11 months
Senior Researcher
Mar 2019 - Dec 2019 · 9 months
Senior Researcher
Jun 2018 - May 2019 · 11 months
Company Details
51-200 Employees
GI Cell was founded by Dr. Myoung Ho Jang, an intestinal immunologist, in Oct 2018. 82 employees (as of Mar 2021) are working in our company and around 40% (15/41) of R&D members are Ph.D. GI Cell has innovative platform technology for screening and optimizing ancillary proteins for target immune cells. Several cell therapy pipelines for treatment of cancer, inflammatory disorders are in the pre-clinical development stages. GI Cell also develop multi-valent sub-unit vaccines for COVID-19 based on experience in ancillary protein engineering and profound understanding in immunology. 1) Immune Cell pure Expander : Platform technology that enables screening and optimizing ancillary proteins to maximize expansion capacity, purity, and functional activity of target immune cells during cultivation. With this optimized ancillary protein, we epigenetically improve NK cell, CD8 T cell, Treg cell to have high potency and targeting efficiency without cancerous feeder cell (in case of NK cell) and genetic engineering. For more information, please visit our websites or contact by e-mail (contact@gi-cell.com).
Year Founded
2018
Social Media
Linkedin
Industry
Pharmaceutical Manufacturing
HQ Location
경기도 성남시 중원구 갈마치로288번길 14, 비동 1553호(상대원동, 성남 SK V1 Tower) 성남 SKV1 Tower 성남시, 경기도 13201, KR
Keywords
--
Discover More About Cleveland Clinic

Find verified contacts of Han-Saem Cho in seconds from 700M people profiles. Start now!

No Credit Card Needed. By signing up, you understand and agree to Futern's Terms and Policy.